论文部分内容阅读
目的:分析丹参酮-ⅡA联合钾钴胺治疗糖尿病周围神经病变的临床疗效。方法:临床选取已确诊的糖尿病住院患者82例,按随机数字表法分为2组,对照组患者给予肌内注射甲钴胺(500μg),qd。治疗组于此基础上,加用丹参酮-ⅡA针剂50 mg静脉滴注,qd,4周为一个疗程,观察患者体内各项指标的变化并分析。结果:治疗组总有效率92.68%;对照组总有效率53.66%,2组比较,差异有统计学意义(P<0.05)。治疗组患者治疗前后血液黏度、纤维蛋白原和红细胞聚集指数都有降低,且差异有统计学意义(P<0.05)。治疗组患者治疗后血液黏度、纤维蛋白原和红细胞聚集指数均较对照组低,2组比较,差异有统计学意义(P<0.05)。治疗组治疗前后腓总神经、正中神经、腓肠神经的神经传导速度有显著提高,差异有统计学意义(P<0.05)。治疗组治疗后腓肠神经的神经传导速度较对照组提高,且差异有统计学意义(P<0.05)。结论:丹参酮-ⅡA与甲钴胺联合治疗糖尿病周围神经病变能明显改善患者血液黏稠度,微循环和神经传导速度等指标,是治疗糖尿病周围神经病变的较好方法,值得临床推广。
Objective: To analyze the clinical efficacy of tanshinone-ⅡA combined with potassium-cobalamin in the treatment of diabetic peripheral neuropathy. Methods: Eighty-two diabetic inpatients were selected clinically. The patients were divided into two groups according to the random number table. The control group was administered intramuscular mecobalamin (500μg) qd. The treatment group on this basis, plus tanshinone-Ⅱ A injection of 50 mg intravenous infusion, qd, 4 weeks for a course of treatment to observe changes in patients with various indicators and analysis. Results: The total effective rate was 92.68% in the treatment group and 53.66% in the control group. There was significant difference between the two groups (P <0.05). The blood viscosity, fibrinogen and erythrocyte aggregation index decreased in the treatment group before and after treatment, and the difference was statistically significant (P <0.05). After treatment, the blood viscosity, fibrinogen and erythrocyte aggregation index in the treatment group were lower than those in the control group. There was significant difference between the two groups (P <0.05). Before and after treatment, the nerve conduction velocity of the common peroneal nerve, median nerve and sural nerve increased significantly in the treatment group, with statistical significance (P <0.05). The nerve conduction velocity of the sural nerve in the treatment group was higher than that in the control group after treatment, and the difference was statistically significant (P <0.05). Conclusion: The combination of tanshinone-ⅡA and mecobalamin in the treatment of diabetic peripheral neuropathy can significantly improve blood viscosity, microcirculation and nerve conduction velocity and other indicators of patients with diabetic peripheral neuropathy is a better way, worthy of clinical promotion.